Morgan Stanley on Eli Lilly (LLY): 'we expect LLY shares to trade flat to slightly up'

Go back to Morgan Stanley on Eli Lilly (LLY): 'we expect LLY shares to trade flat to slightly up'

BMO Capital Reiterates Outperform Rating on Eli Lilly (LLY)

July 2, 2024 3:04 PM EDT

BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $1,001.00 price target on Eli Lilly (NYSE: LLY).

The analyst comments "Approval of donanemab (branded Kisunla) is likely to expand revenue for both Lilly and Biogen/Eisai as two players are needed to grow infrastructure.... More

Eli Lilly Alzheimer's drug approved by US FDA

July 2, 2024 1:55 PM EDT

By Julie Steenhuysen and Mariam Sunny

(Reuters) -The U.S. Food and Drug Administration on Tuesday approved Eli Lilly's treatment for early Alzheimer's, making it the second therapy for slowing progression of the brain-wasting disease that will be available to U.S. patients.

The approval for donanemab, to be sold under the brand name Kisunla, followed the recommendations of the agency's outside experts, who unanimously backed its use in patients with early Alzheimer's disease, saying the benefits of the drug outweighed its risks.

This is real progress," said Joanne Pike of the Alzheimers Association. Having multiple... More

Biogen (BIIB) trades lower after after Lilly's Alzheimer's drug is approved

July 2, 2024 1:55 PM EDT

Shares of Biogen (NASDAQ: BIIB) are trading lower in midday on Tuesday, down nearly 3%, following FDA approval of Eli Lilly's (NYSE: LLY) competing drug to treat Alzheimer's disease.

... More

Eli Lilly & Co. (LLY) Announces FDA Approval of Kisunla to Treat Early Symptomatic Alzheimer's Disease

July 2, 2024 1:36 PM EDT

The U.S. Food and Drug Administration (FDA) approved Kisunla (donanemab-azbt, 350 mg/20 mL once-monthly injection for IV infusion), Eli Lilly and Company's (NYSE: LLY) Alzheimer's treatment for adults with early symptomatic Alzheimer's disease (AD), which includes people with mild cognitive impairment (MCI) as well as people with the mild dementia stage of AD, with confirmed amyloid pathology.1, 2 Once-monthly Kisunla is the first and only amyloid plaque-targeting therapy with evidence to support stopping therapy when amyloid plaques are removed,... More

Midday movers: Tesla, Rivian rise; Novo Nordisk, Pure Storage fall

July 2, 2024 11:50 AM EDT

Investing.com Main U.S. indexes rose Tuesday after Fed Chairman Jerome Powell pointed out progress on inflation during a panel discussion with officials from the European Central Bank. Overall trading volumes were lighter than normal ahead of the holiday on Thursday.

Here are some of the biggest U.S. stock movers today:

Tesla (NASDAQ:... More

Eli Lilly & Co. (LLY) call put ratio 1 call to 1.2 puts with focus on August 870 and 890 calls

July 2, 2024 10:47 AM EDT

Eli Lilly & Co. (NYSE: LLY) 30-day option implied volatility is at 25; compared to its 52-week range of 19 to 39. Call put ratio 1 call to 1.2 puts with focus on August 870 and 890 calls.

... More

Novo Nordisk, Eli Lilly stock slides after Biden op-ed calls for lower Ozempic, Wegovy Prices

July 2, 2024 9:12 AM EDT

Shares of Eli Lilly & Co. (NYSE: LLY) and Novo Nordisk (NYSE: NVO) fell by more than 2% and 3%, respectively, premarket Tuesday after U.S. President Joe Biden said Novo Nordisk must cut Ozempic and Wegovy... More

Biden Says Novo Nordisk (NVO) Must Cut Ozempic, Wegovy Prices

July 2, 2024 8:00 AM EDT

(Updated - July 2, 2024 8:05 AM EDT)

(Updated - July 2, 2024 8:01 AM EDT)

Biden Says Novo Nordisk (NVO) Must Cut Ozempic, Wegovy Prices

Biden Comments In USA Today Op-ed With Senator Bernie... More

Radionetics Oncology Enters Into Strategic Agreement With Lilly (LLY)

July 1, 2024 10:05 AM EDT

Radionetics Oncology, a biotechnology company discovering and developing novel small molecule G protein coupled receptor (GPCR) targeted radiopharmaceuticals to treat a broad range of solid tumors, announced today the formation of a strategic relationship with Eli Lilly and Company to take forward Radionetics proprietary GPCR targeting small molecule radiopharmaceuticals.

Under the terms of the agreement, Radionetics received a $140 million upfront cash payment. As... More

Eli Lilly & Co. (LLY) option implied volatility flat as share price near record high

June 28, 2024 10:26 AM EDT

Eli Lilly & Co. (NYSE: LLY) 30-day option implied volatility is at 23; compared to its 52-week range of 19 to 39 as share price near record high.

... More